The most influential Megatrends set to shape the world through 2030, identified by Euromonitor International, help businesses better anticipate market developments and lead change for their industries.
Learn moreEuromonitor addresses your unique questions and challenges across all B2B and B2C industries and geographies through custom, tailor-made research projects, designed to your specific goals.
Learn moreOct 2017
US$1,325Added to Cart
If you purchase a report that is updated in the next 60 days, we will send you the new edition and data extract FREE!
If you purchase a report that is updated in the next 60 days, we will send you the new edition and data extract FREE!
Asia Pacific is the second largest region in the world for analgesics sales behind North America and is also the fastest growing region, driven by an ageing population and an increasing preference for topical analgesics over systemics. Looking forward to 2022, Asia Pacific is expected to continue growing at a rapid pace and to overtake North America as the largest global market by 2019 with USD6.0 billion in sales to North America’s USD5.6 billion.
Files are delivered directly into your account within a few minutes of purchase.
Gain competitive intelligence about market leaders. Track key industry trends, opportunities and threats. Inform your marketing, brand, strategy and market development, sales and supply functions.
Over the review period 2012-2017, analgesics sales in the world’s largest regional market of North America posted a CAGR of 1% to reach total retail value sales of USD5.9 billion in 2017, while analgesics sales in Asia Pacific posted a CAGR of 4% over 2012-2017 (outpacing the global CAGR of 2%) to reach total retail value sales of USD5.6 billion. While growth in North America is expected to be sluggish over the forecast period 2017-2022, growth in Asia Pacific will continue at a rapid rate, resulting in Asia Pacific overtaking North America by 2019.
Topical analgesics are historically quite popular in the Asia Pacific region and growing very rapidly in China, where category sales posted a CAGR of 7% over 2012-2017 to reach total retail value sales of USD996 million in 2017. Looking ahead, topicals in China are expected to continue to grow at a projected CAGR of 7% to reach estimated sales of USD1.4 billion in 2022, representing absolute value growth of USD385 million. China’s increasingly elderly population reports preferring topical analgesics when treating pains associated with old age such as arthritis.
GlaxoSmithKline ended 2017 with more than 8% of the total market for analgesics across the region, representing a sales CAGR of 9% since 2012 and absolute retail value growth of USD161 million over that time. GSK’s sales were lifted by strong growth of its acetaminophen brand Panadol, as well as the 2014 acquisition of Voltaren and Kaflan from Novartis, both of which have experienced steady positive growth since 2014.
Despite the popularity of GSK’s analgesic brands, Hisamitsu’s Salonpas retained its position as the most popular analgesic brand on the market, growing at a historic CAGR of 6% to reach total sales of USD239 million in 2017. Consumers’ familiarity with the Salonpas name and preference for topicals helped push the brand’s growth.
Gain competitive intelligence about market leaders. Track key industry trends, opportunities and threats. Inform your marketing, brand, strategy and market development, sales and supply functions.